Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice

Arthritis and Rheumatism

Volumn 52, Issue 12, 2005, Pages 3987-3996

  Sadanaga, Atsushi ^a   Nakashima, Hitoshi ^a   Masutani, Kohsuke ^a   Miyake, Katsuhisa ^a   Shimizu, Sakiko ^a   Igawa, Takashi ^a   Sugiyama, Naonobu ^a   Niiro, Hiroaki ^a   Hirakata, Hideki ^a   Harada, Mine ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DOUBLE STRANDED DNA; IMATINIB; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; EXTRACELLULAR MATRIX; FEMALE; GENE MUTATION; GLOMERULONEPHRITIS; HIGH RISK PATIENT; HISTOPATHOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE ACTIVATION; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLENOMEGALY; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; BLOOD UREA NITROGEN; CD4-POSITIVE T-LYMPHOCYTES; CREATININE; DNA; FEMALE; GLOMERULONEPHRITIS; IMMUNOGLOBULIN G; INTERFERON TYPE II; LUPUS NEPHRITIS; LYMPHATIC DISEASES; MICE; MICE, INBRED MRL LPR; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEINURIA; PYRIMIDINES; SALIVARY GLANDS; SEVERITY OF ILLNESS INDEX; SPLEEN; SPLENOMEGALY; SURVIVAL ANALYSIS;

EID: 29144476588     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21424     Document Type: Article

References (36)

1. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991;9:243-69.
2. Van Parijs L, Abbas AK. Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol 1996;8:355-61.
3. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985;37:269-390.
4. Floege J, Johnson RJ. Multiple roles for platelet-derived growth factor in renal disease. Miner Electrolyte Metab 1995;21:271-82.
5. Shultz PJ, di Corleto PE, Silver BJ, Abboud HE. Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am J Physiol 1988;255:F674-84.
6. Floege J, Johnson RJ, Alpers CE, Fatemi-Nainie S, Richardson CA, Gordon K, et al. Visceral glomerular epithelial cells can proliferate in vivo and synthesize platelet-derived growth factor B-chain. Am J Pathol 1993;142:637-50.
7. Nicolic-Paterson DJ, Atkins RC. Macrophages in immune renal injury. New York: Raven Press; 1997.
8. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A 1992;89:2873-7.
9. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M. PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995;48:111-7.
10. Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992;175:1413-6.
11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
12. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002;38 Suppl 5:S28-36.
13. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
14. Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000;60:5143-50.
15. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, dal Cin P, Buchdunger E, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61:5778-83.
16. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359:1577-8.
17. Cools J, de Angelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
18. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-6.
19. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, et al. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001;59:1324-32.
20. Iida H, Seifert R, Alpers CE, Gronwald RG, Phillips PE, Pritzl P, et al. Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc Natl Acad Sci U S A 1991;88:6560-4.
21. Gesualdo L, Pinzani M, Floriano JJ, Hassan MO, Nagy NU, Schena FP, et al. Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis. Lab Invest 1991;65:160-7.
22. Frampton G, Hildreth G, Hartley B, Cameron JS, Heldin CH, Wasteson A. Could platelet-derived growth factor have a role in the pathogenesis of lupus nephritis? [letter] Lancet 1988;2:343.
23. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994;331:1286-92.
24. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004;104:1094-9.
25. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004;18:1332-9.
26. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105:2473-9.
27. Baskaynak G, Kreuzer KA, Schwarz M, Zuber J, Audring H, Riess H, et al. Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. Eur J Haematol 2003;70:231-4.
28. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003;9:976-80.
29. Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003;22:329-32.
30. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of cyclosporin A and FK506 [review]. Clin Immunol Immunopathol 1996;80:S40-5.
31. Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Week MM, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004;103:538-44.
32. Agosti V, Corbacioglu S, Ehlers I, Waskow C, Sommer G, Berrozpe G, et al. Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J Exp Med 2004;199:867-78.
33. Haas C, Ryffel B, le Hir M. IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J Immunol 1997;158:5484-91.
34. Kikawada E, Lenda DM, Kelley VR. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-γ expression, and diminishes systemic pathology. J Immunol 2003;170:3915-25.
35. Balomenos D, Rumold R, Theofilopoulos AN. The proliferative in vivo activities of lpr double-negative T cells and the primary role of p59fyn in their activation and expansion. J Immunol 1997;159:2265-73.
36. Lawson BR, Prud'homme GJ, Chang Y, Gardner HA, Kuan J, Kono DH, et al. Treatment of murine lupus with cDNA encoding IFN-γR/Fc. J Clin Invest 2000;106:207-15.